Mink Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Mink Therapeutics

12/08/2025 14:22

Mink Therapeutics Inc INKT.OQ INKT.O is expected to  show no change in quarterly revenue when it reports  results on August 14 for the period ending June 30 2025

​LSEG's mean analyst estimate for Mink Therapeutics Inc is for a loss of 55 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Mink Therapeutics Inc is $39.00, about 68.7% above its last closing price of $12.22

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.60
-0.61
-0.70
Missed
-14.8
Dec. 31 2025
-0.50
-0.62
Missed
-24
Sep. 30 2024
-0.80
-0.80
-0.50
Beat
37.5​
Jun. 30 2024
-0.98
-1.00
-0.70
Beat
30
​​Mar. 31 2024
-1.58
-1.53
-1.10
Beat
28.3
Dec. 31 2023
-1.53
-1.60
Missed
-4.3​
Sep. 30 2023
-1.79
-1.82
-1.50
Beat
17.8
Jun. 30 2023
-1.91
-1.97
-1.80
Beat
8.9

This summary was machine generated August 12 at 13:22 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)